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 Progression of renal disease is a worldwide increasing problem. Over the last decades, 
important progress has been made to optimize treatment strategies for patients with chronic 
renal disease. In many patients blockade of the RAAS, by Angiotensin Converting Enzyme-
inhibition (ACEi) and Angiotensin II type 1 antagonists (AT1-A) is effective in reducing blood 
pressure and proteinuria, thereby ameliorating the rate of renal function loss. However, in many 
patients progressive loss of renal function still occurs, eventually leading to end-stage renal 
damage, reflecting resistance of the renal condition to the therapeutic effects of RAAS-blockade. 
Therefore, it is crucial to elucidate the mechanisms underlying the resistance to therapy, as 
identification of these factors allows designing novel renoprotective treatment regimen.  
 
 Unlike, for instance, the field of oncology, in nephrology the mechanisms of resistance to 
pharmacological intervention have not been a major research topic, and consequently, the 
determinants of response or resistance to renoprotective intervention are not well understood, 
although it has been shown consistently that dietary sodium restriction can potentiate the 
response to RAAS-blockade. Yet, the observation that the reduction of proteinuria during 
therapy predicts the long-term renal prognosis provides a useful starting point. Moreover, it 
would be logical to assume that intrarenal factors are involved in the response to therapy, but 
there is hardly any data on this, because in renal patients renal tissue is only available for 
investigation when the clinical condition and the therapeutic options justify a renal biopsy. 
Interestingly, however, a retrospective study in transplant recipients showed that the 
antiproteinuric efficacy of fosinopril was determined by the extent of tubulointerstitial lesions [1].  
 
This report raised the hypothesis that tubulointerstitial lesions are a determinant of renal 
responsiveness or resistance to RAAS-blockade. This hypothesis is difficult to test in man, 
however, as it requires a pretreatment renal biopsy in all patients, preferably all with a similar 
renal condition. Therefore, to prospectively test the hypothesis that interstitial lesions determine 
the antiproteinuric response to RAAS-blockade, we used a model of chronic proteinuria-induced 
renal damage in rats, namely adriamycin nephropathy. In chapter 2 we showed that the extent of 
renal damage present before the start of treatment is indeed prognostic for antiproteinuric 
efficacy of RAAS-blockade. The early interstitial lesions were positively correlated with 
proteinuria at time of biopsy, and moreover, they predicted the antiproteinuric response after 2 
weeks and 6 weeks of treatment. Thus, in animals with more pronounced early interstitial lesions, 
the antiproteinuric response was suboptimal compared to animals with less early interstitial 
lesions. The renal damage prior to treatment with ACEi was prognostic for both the short-term 
antiproteinuric responses as well as for the severity of structural glomerular damage, i.e. focal 
glomerulosclerosis after longer follow up. These prospective findings thus are consistent with the 
prior report in transplant recipients [1]. For ethical reasons, the data cannot easily be confirmed 
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in patients. Nevertheless, some clinical studies have been performed that used protocol biopsies, 
and for the future it would be interesting to study whether the tubulointerstitial lesions in these 
protocol-biopsies predict the response to RAAS-blockade. The prognostic impact of the early 
tubulointerstitial lesions for the antiproteinuric response is all the more remarkable as the early 
reduction in proteinuria is considered to be primarily mediated by therapeutic effects on the 
glomerulus, i.e. the direct reduction of glomerular pressure by efferent vasodilatation, and the 
indirect reduction of glomerular pressure by the lower blood pressure.   
The prognostic impact of the intrarenal lesions present at onset of therapy for the 
response to therapy is of great clinical impact. Renal damage can go largely unnoticed, and 
consequently, most renal patients come under medical attention not until some extent of 
established renal damage is present. So, this observation provided the starting point for the 
further studies in this thesis, that addressed the prognostic impact of tubulointerstitial as well as 
glomerular lesions at onset of treatment for the renoprotective effects of RAAS-blockade, the 
possible reversibility of these intrarenal factors during RAAS-blockade to determine whether 
their persistence during therapy might be a factor in therapy resistance, and finally, strategies to 
overcome resistance to RAAS-blockade. 
 
Part I: Intrarenal factors and therapy resistance 
To gain insight in the intrarenal mechanisms of resistance to RAAS-blockade we studied 
several intrarenal factors previously suggested to be involved in the pathogenesis of renal 
damage. As interstitial α-smooth muscle cell actin (α-SMA) expression - a marker of the pre-
fibrotic myofibroblast transformation – was the best predictor of the antiproteinuric response in 
our first study, we studied two tubular cell related factors possibly upstream in this process, i.e. 
Osteopontin and Kidney injury molecule-1 (Kim-1). Moreover, we studied whether these 
proteins might be suitable as targets for intervention or monitoring of therapeutic efficacy by 
measurement in urine or blood. Second, as proteinuria is largely due to defects in the glomerular 
basement membrane (GBM), we also studied two glomerular factors involved in the maintenance 
of the integrity of the basement membrane, i.e. the expression of heparan sulfate and its 
association with heparanase in chronic proteinuria-induced renal damage and during treatment 
with an AT1-A. 
Osteopontin is a molecule involved in the attraction of monocytes and macrophages, and 
is upregulated in several models of renal injury. In Chapter 3 we studied the time-course of renal 
osteopontin induction in relation to proteinuria, the influx of macrophages into the renal 
interstitium and the development of structural damage. Osteopontin - present in injured proximal 
tubular cells – increased progressively over time and was strongly correlated with proteinuria, 
suggesting that proteinuria itself induces osteopontin expression. In a second study animals 
underwent a biopsy before ACEi treatment was started. In this study the reduction of proteinuria 
was accompanied by a reduction of osteopontin protein and a stabilization of osteopontin 
 




mRNA, whereas in untreated animals osteopontin protein stabilized and osteopontin mRNA 
dramatically increased. So, by antiproteinuric treatment with ACEi, the upregulation of 
osteopontin was reversible, however without a corresponding reduction in fibrosis. Data in 
osteopontin knock-out mice and from treatment with anti-osteopontin antibodies [2;3] support a  
role of upregulation of osteopontin in the pathogenesis of proteinuria-induced interstitial fibrosis, 
so theoretically osteopontin could be an additional target for therapy. In other studies, however, 
osteopontin protected the interstitium from macrophage infiltration and interstitial fibrosis, 
suggesting protective effects as well. From the perspective of identifying targets for intervention 
it is important that our intervention with ACEi showed that reduction of osteopontin does not 
attenuate established fibrosis. Thus, osteopontin does not qualify as a suitable target for 
intervention in addition to RAAS blockade.    
A new player in the tubulointerstitium, Kidney injury molecule-1 (Kim-1), is expressed in 
acute renal disease in human and experimental animal in injured tubules. In chapter 4 we showed 
that Kim-1 expression is induced in proteinuric renal disease, and that the Kim-1 ectodomain is 
shedded into urine. This is not unique to adriamycin nephrosis, but also to other models of 
chronic renal damage, such as protein-overload nephrosis and hypertensive renal damage [4;5]. 
Pharmacological intervention with ACE-i and AT1-A reduced both renal and urinary Kim-1 
levels. Kim-1 is present at the apical membrane of tubules with mild to moderate damage, as 
indicated by slight dilatation, however it is not present when tubular cell damage is severe. The 
reduction of Kim-1 during RAAS-blockade along with proteinuria suggests that Kim-1, just like 
osteopontin is not a suitable target for intervention in the pathway of progressive 
tubulointerstitial fibrosis. However, since Kim-1 is closely associated with tubulointerstitial injury 
and shedded into urine, it might be a marker for activity of the cascade of proteinuria-induced 
tubulointerstitial damage – and thus a marker for the efficacy of therapy on the intrarenal 
processes downstream of proteinuria. If so, this would be of great clinical importance as it might 
be used to guide therapy. Unfortunately, we could not investigate this properly, as only urine of 
week 12 was available for measurement of Kim-1, and the value of urinary Kim-1 as marker for 
responsiveness or resistance to therapy (in addition to proteinuria) therefore remains to be 
studied. The functional role of Kim-1 would also be of interest for future studies. Kim-1 might 
be protective against toxic effects of excessive proteins and growth factors, but it might also have 
a harmful effect at the surrounding tubules and interstitium. The pattern of staining directs 
mostly towards a protective function.  
In addition to tubulointerstitial lesions we also studied the role of integrity of the 
glomerular basement membrane (GBM) - which is a main determinant of proteinuria - in the 
response to therapy. Heparan sulfates are important constituents of the slit diaphragm and loss of 
heparan sulfates is associated with an altered charge-dependent permeability of the glomerular 
basement membrane (GBM). In an earlier study it was shown that loss of GBM heparan sulfate 
was due to reactive oxygen species (ROS), and ROS scavengers - such as dimethylthiourea 
 
Summary and future perspectives 
 
 127 
(DMTU) - could partially prevent the loss of GBM heparan sulfate and partially reduce 
albuminuria. Thus, ROS cannot completely account for the loss of GBM HS and the induction 
of albuminuria.  Recently, heparanase – an enzyme capable of degrading heparan sulfate 
polysaccharide side chains - was found to be increased in diabetic nephropathy [6]. In chapter 5 
we studied whether heparanase is resposible for loss of GBM heparan sulfate and induction of 
proteinuria in adriamycin nephrosis. Second, the effect of the ROS scavenger DMTU on 
heparanase expression was studied. Finally, we studied the effect of RAS blockade on heparanase 
expression and its relevance for therapy resistance. We found that loss of heparan sulfate was 
strongly associated with increased heparanase-activity. Treatment with ROS-scavengers during 
induction of adriamycin nephrosis reduced heparanase expression compared saline treated 
adriamycin animals. Finally, in established adriamycin nephroisis, antiproteinuric treatment with 
AT1A reduced the expression of heparanase with a subsequent increase in heparan sulfates. 
Thus, the reduced heparanase expression after treatment with DMTU supports the involvement 
of hydroxyl radicals in the induction of heparanase expression, which subsequently leads to loss 
of GBM HS and development of proteinuria in AN. Moreover, the induction of heparanase in 
AN was reversible by AT1A. This suggests that angiotensin II has a role in heparanase induction 
– and that amelioration of heparanase induction, and the subsequent restoration of GBM HS, 
contributes to the beneficial effects of RAS-blockade. However, in contrast to tubulo-interstitial 
lesions in the previous chapters, GBM heparan sulfate and glomerular heparanase expression did 
not predict antiproteinuric response and interstitial fibrosis during follow up, suggesting that HS 
and heparanase activity are not limiting factors for therapy response. This might be due to the 
short follow-up, however in earlier studies tubulointerstitial markers already predicted 
antiproteinuric effect after 2 weeks.  
HS and heparanase were not restored to normal levels, suggesting they could provide a 
target for additional intervention. Recent studies show that anti-heparanase treatment in 
experimental nephrosis reduces proteinuria [7;8]. Also studies using heparin or low molecular 
weight (LMW) heparin showed a reduction of albuminuria in diabetic patients [9-12]. These 
heparins and LMW heparins consist a mixture of glycosaminoglycans, mainly heparan sulfate. 
Thus, together, the above studies suggest that intervention directed at restoration of heparan 
sulfates in the glomerular basement membrane might result in an anti-proteinuric effect, however 
whether it is has additional effects on top of RAS blockade and improves long-term outcome, 








Part II: Strategies to overcome the renal resistance to RAAS blockade 
Our finding that early interstitial damage is prognostic for the anti-proteinuric efficacy of 
ACEi, could raise the impression that the prognosis is already set by the time treatment is started. 
This would be particularly disquieting, as renal disease goes often unnoticed in man, and most 
patients have at least some degree of renal structural damage by the time they come to medical 
attention (with type I diabetes as the main exception). However, the prognostic value of 
pretreatment renal damage should not be a reason for therapeutic nihilism, but rather prompt the 
search for treatment strategies to overcome the renal therapy resistance.  
In chapter 6 we demonstrated that modification of sodium status could overcome the 
prognostic value of early renal damage on antiproteinuric efficacy. Adriamycin nephrotic animals 
were instituted on different oral sodium intakes, and underwent a biopsy before treatment with 
ACEi was started. During high sodium diet the antiproteinuric effect was absent, but during 
normal and low sodium diet proteinuria was reduced to normal values. However, during normal 
and high sodium diet extensive early interstitial lesions were still associated with worse 
antiproteinuric efficacy after 3 or 6 weeks of treatment and structural damage after 6 weeks of 
treatment. On the opposite, this prognostic value was absent in rats treated with low sodium and 
ACEi. Thus, the prognostic value of interstitial lesions is modifiable by intervention strategies. 
Importantly, especially the individuals with high residual proteinuria (i.e. those with a poor 
prognosis) benefit from additional treatment, such as sodium restriction, to ACEi.   
In chapter 7 we tested the efficacy of the aldosterone receptor blocker (aldoRB) 
spironolactone, a diuretic with anti-fibrotic effects, in combination with ACEi on proteinuria and 
renal damage. Aldosterone has - in addition to its role in sodium conservation - pro-fibrotic 
properties [13;14], and moreover, it is increased in a substantial part of the patients as an escape-
mechanism during ACEi [15]. In our study, treatment with ACEi and the combination of ACEi 
with aldoRB reduced proteinuria and blood pressure, whereas aldoRB alone could not reduce 
proteinuria and blood pressure, which was comparable with other studies [16;17]. Although no 
significant difference between ACEi and ACEi/aldoRB for proteinuria and blood pressure were 
detected, tubular damage on the other hand- quantified by measurement of osteopontin and 
Kim-1 mRNA and protein – was reduced in the ACEi/aldoRB group only. Thus, combining 
ACEi and aldoRB was effective, however, there was no additional effect compared to ACEi 
alone. Future studies need to explore whether combining ACEi with aldoRB (eventually with the 
selective aldosterone blocker eplerenone) has additive effects compared to combining ACEi with 
low sodium. A recent paper showed that treatment with aldoRB by spironolactone reduced 
glomerulosclerosis in rats with 5/6 nephrectomy. When combined with antihypertensive 
treatement even regression of glomerulosclerosis was observed [18]. Thus, the effects of aldoRB 
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Future perspectives  
In this thesis we demonstrate that the extent of renal damage present before start of 
treatment determines the antiproteinuric efficacy of RAAS-blockade. This might seem intuitively 
obvious, but on closer screening, it is a puzzling finding, with great potential relevance for the 
clinical setting as in man structural renal damage is often already present by the time of start of 
treatment. Moreover, it is intriguing that the relatively mild changes, that are not even apparent at 
routine morphology, interfere with therapeutic efficacy. How can we put these findings into 
effect to design better renoprotective strategies? Various strategies present themselves here, 
namely: first, pursue earlier detection of renal disease and start of treatment, and second, identify 
the specific pathways of therapy resistance and ongoing renal damage during RAAS-blockade, 
and finally, design additional modes of intervention.  
The concept of early detection and early start of treatment, even before overt renal 
damage has developed is under investigation currently, and has proven to be successful in 
diabetic patients, as for instance in the recent BENEDICT trial, that showed that treatment with 
ACEi retarded the onset of microalbuminuria in hypertensive patients with type 2 diabetes [19]. 
Proof of concept for the long-term benefit of intervention during the stages that precede renal 
damage was provided by Nagai et al showed that in type 2 diabetic rats, temporary angiotensin II 
blockade at the pre-diabetic stage attenuated the development of renal injury [20].   
 
How to identify patients with ongoing renal damage during RAAS-blockade?   
The predictive effect of proteinuria reduction for long-term renoprotection is well-
established in many conditions, and it is generally assumed that proteinuria closely reflects the 
mechanisms of ongoing renal damage. If so, proteinuria (along with blood pressure) would be the 
only factor needed to identify patients with ongoing renal damage. However, proteinuria and 
renal damage can be dissociated – thus hampering the predictive power of proteinuria, and 
requiring more direct measures of the intrarenal processes of tubulointerstitial damage 
downstream of proteinuria. In this respect we want to emphasize the finding in chapter 6, where 
we found that sodium restriction could overcome the negative effects of pre-treatment renal 
damage on the anti-proteinuric response, without, however, a benefit on interstitial damage. In 
recent other studies from our group, in fact, we found that in proteinuric rats the combination of 
ACEi and sodium restriction elicits pronounced interstitial lesions despite a significant reduction 
of proteinuria. The same abnormalities were found in healthy rats on the same regimen [21], 
strongly suggesting a link to this specific therapeutic regimen. Whereas the mechanism underlying 
the dissociation between proteinuria and renal damage requires further investigation, it also 
strongly underlines the need for non-invasive markers other than proteinuria that reflect the 
intrarenal pathways of damage. Studies that have to establish whether urinary Kim-1 is such a 
marker reflecting early tubulo-interstitial damage are currently under way. In addition to non-
invasive markers of early tubulointerstitial damage, biomarkers of more advanced 
 




tubulointerstitial damage, such as urinary collagen typ IV, should be studied for their prognostic 
value for therapy response, and for their value in titrating therapy to improve long-term outcome. 
Urinary type IV collagen is a candidate marker for the detection of advanced renal injury, as it is 
significant increased in various types of renal disease compared to healthy controls [22]. 
Moreover, urinary type IV collagen is correlated with renal injury in IgA nephropathy [23].   
 
How to identify intrarenal pathways responsible for therapy resistance?  
The process of ongoing renal damage during therapy is complex and likely involved many 
factors. Identifying the key players is likely to be difficult, and may be like looking for a needle in 
a haystack. Our data show, that it is important to investigate the determinants of treatment 
response at tissue level, and not only monitor efficacy exclusively from clinical parameters like 
blood pressure and proteinuria. In this thesis we only tested only a small number of intrarenal 
factors, and by these examples we can illustrate a more general strategy to be used in screening 
the kidney for factors involved in therapy resistance. In our studies osteopontin and Kim-1 
expression predicted therapy response, but despite the reduction of osteopontin and Kim-1 along 
with proteinuria during therapy, the interstitial fibrosis was not reversible. Therefore, osteopontin 
and Kim-1 are not suitable targets for additional intervention. Altered glomerular heparanase 
expression and GBM HS, on the other hand, did not predict short-term antiproteinuric efficacy 
neither progression of interstitial fibrosis, but were partly reversible upon treatment, possibly 
contributing to the antiproteinuric effect. So, intervention aimed at amelioration of the increased 
permeability of the GBM due to loss of heparan sulfate might be useful for further reduction of 
proteinuria, but is not likely to have direct effects on the progression of interstitial fibrosis. 
Finally, α-SMA was a consistent predictor of therapy response, that was not ameliorated at all 
during RAAS-blockade, and neither did collagen deposition. This suggests that fibroblasts and 
factors influencing the activation and proliferation of the fibroblast are important determinants 
of ongoing renal damage during RAAS blockade and may therefore by suitable targets for new 
modes of intervention in the progression of renal disease.  
As mentioned above, the search for the factors responsible for the resistance to RAAS-
blockade resembles looking for a needle in a haystack. However with new high throughput 
techniques, such as micro-arrays, proteomics, and kinomics the expression of hundreds of genes, 
and proteins, respectively, can be tested simultaneously. To select the ones with 
pathophysiological relevance for therapy response, the various response-patterns can be analysed 
by the scheme in Figure 1, that depicts the different possibilitities of response to therapy. The 
schedule helps to indetify intermediate factors involved in therapy resistance as follows. First, in 
the situation that RAAS-blockade reduces proteinuria, the factor of interest (intermediate factor) 
is reduced and also long-term structural damage, there is no therapy resistance but a good 
response (situation A). However, when proteinuria is partly or completely reduced, and the 
intermediate factor is reduced while structural damage is not improved, the latter outcome should 
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be classified as therapy resistance. Whereas, in this situation (B), the intermediate factor may be a 
predictor of therapy resistance, it is not, however, a causal factor in therapy resistance, as it 
dissociates from the eventual outcome. In the third situation (C) the intermediate factor has not 
changed during RAAS-blockade (with reduction of proteinuria) but structural damage is reduced, 
which means that there is no therapy resistance and this intermediate factor is not relevant. In the 
final situation (D) both the intermediate factor and structural damage are not reduced by RAAS-
blockade, indicating that therapy resistance has occurred and that the intermediate factor may 
well be involved in therapy resistance. The intermediate factors that follow the pattern from 
situation D are potential factors for intervention in addition to RAAS-blockade and when 
possible to measure in urine or serum, might also function to monitor the efficacy of treatment.  
RAAS blockade: 
Proteinuria     or = 
Intermediate factor  Intermediate factor Intermediate factor = Intermediate factor =















Figure 1. Theoretical model for the screening of potential factors of therapy resistance that are of interest 
for intervention and monitoring of proteinuric renal disease. 
 
New treatment strategies 
In addition to the screening for important factors, development of therapeutic strategies 
needs to go on. The alleged effect of pro-fibrotic changes in therapy resistance suggest that new 
strategies to prevent the progression of renal damage should be directed at profibrotic factors 
such as Angiotensin II and TGF-β1 or in pathways downstream of these factors. A promising 
novel approach to the treatment of renal disease is through inhibition of adamalysins [24]. These 
proteins, which are abundantly present in the kidney, are involved in shedding of fibrogenic 
growth factors and cytokines from the cell membrane. Furhermore, for the reversal of structural 
damage, proteases that degrade excessive matrix accumulation are of interest. However, there 
remains a risk that these proteases not only reduce the excessive matrix but also the normal 
matrix necessary for cell-cell adhesion and stability.  Intervention directed towards TGF-β1 is 
already shown to be efficient in animals [25], and can also be directed at downstream pathways 
such as the smad- pathway [26]. Addition of statins to the regular treatment regime, is capable of 
reducing cardiovascular morbidity but experimental data showed that statins are also capable of 
reducing proteinuria [27]. Statins have also been reported to induce proteinuria; however, this is a 
mild tubular proteinuria, mediated by the reduction of receptor-mediated endocytosis in proximal 
tubular cells by statins [28] and therefore, we consider this mild proteinuria not likely to induce 
 




tubulointerstitial injury. Finally the addition of aldosterone-blockade to current treatment 
strategies can be useful for long-term renoprotection, as we showed a protective value in this 
thesis and others recently found reversibility of glomerulosclerosis by combining antihypertensive 
treatment with aldosterone-blockade [18].   
As we showed earlier, fibroblasts are important in the progression of renal disease and 
therefore intervention should be directed on the proliferation and activation of fibroblasts. 
Fibroblasts are derived from several sources, which makes intervention less easy. It has been 
estimated that about 35% of the fibroblasts are derived from local epithelial to mesenchymal 
transition (EMT), which are tubular epithelial cells under (inflammatory) stress that transformed 
into fibroblasts. Second, circa 15% of the fibroblasts are derived from the bone marrow. And 
finally the rest is contributed by proliferating fibroblasts mainly from the interstitial space [29;30]. 
TGF-β1 induces EMT and also activates fibroblasts to proliferate. Interestingly, all these actions 
of TGF-β1 can be counteracted by bone morphogenic protein-7 (BMP-7) [31]. BMP-7 reduces 
interstitial fibrosis in a mouse model of progressive chronic renal injury (nephrotoxic serum 
nephritis) [32]. Together with BMP-7 hepatocyte growth factor is capable of reducing EMT as 
well, and thereby reducing interstitial fibrosis [33;34]. Intervention in the process of EMT may 
therefore be of interest for better prevention of long-term proteinuria-induced renal damage. 
Another innovative possibility for intervention would be modulation of stem cell function. 
Theoretically, improvement of endogenous stem cell function, or administration of exogenous 
stem cells could contribute to renal repair processes and reversibility of renal damage. As, 
however, stem cells in themselves can also contribute to fibrotic processes, in-depth studies 
aimed at purposeful modulation of stem cell function are needed [35]. 
 
Implications for clinical practice 
This thesis shows that the extent of renal damage present before the start of treatment 
predicts the outcome of therapy with RAAS-blockers. Whether this also applies to human renal 
disease needs to be confirmed in further studies, which could be done in the protocol-biopsy 
studies that are available. It is important to note that, nothwithstanding the predictive effect, the 
renal prognosis during therapy is still modifiable by optimizing therapeutic measures, as we 
showed for sodium restriction. Whether this also holds true for other measures that potentiate 
the effects of RAAS-blockade, such as dual blockade (combining ACEi with AII antagonist) or 
combining ACEi with aldosterone-antagonists, remains to be studied. At any rate, our data show 
that the prognostic impact of pre-treatment renal damage is not a fixed phenomenon, and that 
intensifying the therapeutic regimen can overcome the prognostic impact of pre-treatment 
damage on anti-proteinuric response. However, recent data from our group also direct that 
titration to low blood pressure values might be harmful as well, and induce interstitial lesions that 
dissociate from the further reduction of proteinuria [21]. Moreover, in man, the feasibility of 
agressive titration of RAAS-blockade-based therapy may be limited by a poor tolerability [36]. 
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Together, these findings indicate, first, that it would be important to design additional modes of 
intervention, and second, that it would be useful to have non-invasive biomarkers for monitoring 
renal tubulo-interstitial damage directly, as the prognostic impact of proteinuria, although 
important, is apparently not perfect. Further reduction of proteinuria by restoring the 
permeability characteristics of the GBM by low molecular weight heparin and added heparan 
sulfates could provide such an additional mode of intervention. Moreover, one could imagine 
that in the future, patients with chronic renal disease will be treated with the conventional 
treatment strategies such as RAAS-blockade and measures that optimize RAAS-blockade, as 
assessed from the reduction of proteinuria, and that based on increased levels of biomarkers, 
additional treatment will be given to prevent ongoing progression of renal damage. Such 
additional strategies could be aimed at directly interfering with the processes of tubulo-interstital 
fibrosis downstream of proteinuria, for instance by targeting EMT.  
 
In conclusion, this thesis showed that the glomerular lesions responsible for initial protein 
leakage and early tubular lesions are reversible during treatment with RAAS-blockade. However 
interstitial lesions are not reversible with the treatment regimens used in this thesis. Interestingly, 
these irreversible interstitial lesions are predictive for therapy resistance. Thus, with the current 
treatment strategies, the clue to resolution of resistance to the renoprotective effects of RAAS-
blockade probably lies in the interstitium. Innovative therapies such as intervention in the EMT 
process and stem cell therapy are being developed currently. Until their feasibility in patients has 
been demonstrated, renoprotective treatment should be guided by the individual response to 
therapy, monitoring blood pressure and proteinuria as well as possible adverse effects during 
treatment schedules aimed at optimizing the response to RAAS blockade by dual blockade, and 
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